EUCTR2004-004696-11-DK进行中（未招募）1 期
A open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 217
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. written informed consent provided prior to participation in the extension study
- •2. successful completion of study CSMS995 0802
- •3. willingness to comply with all study requirements
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. more than 8 weeks interval since the completeion of study CSMS995 0802
- •2. premature discontinuation from study CSMS995 0802
研究者
相似试验
进行中（未招募）
1 期
A open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathyModerately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathyEUCTR2004-004696-11-ESovartis Farmacéutica, S.A.
进行中（未招募）
不适用
A open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathyModerately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathyEUCTR2004-004696-11-ATovartis Pharma Services AG217
进行中（未招募）
1 期
A open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathyEUCTR2004-004696-11-FIovartis Pharma Services AG
进行中（未招募）
不适用
A open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathyModerately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathyEUCTR2004-004696-11-SEovartis Pharma Services AG217
进行中（未招募）
不适用
A open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathyModerately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathyEUCTR2004-004696-11-GBovartis Pharma Services AG217